<DOC>
	<DOC>NCT01232543</DOC>
	<brief_summary>The aim of the trial is to assess Adrenal Suppression potential when pediatric subjects are administered Product 0405 for the treatment of Atopic Dermatitis</brief_summary>
	<brief_title>Safety Study Evaluating the Adrenal Suppression Potential of Product 0405 in Pediatric Subjects With Atopic Dermatitis</brief_title>
	<detailed_description>Treatment medication will be administered topically, twice a day for 4 weeks.</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Clinical diagnosis of Atopic Dermatitis Good health with the exception of Atopic Dermatitis Percent body surface area minimum requirements Subjects who are pregnant, nursing, or planning a pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Atopic Dermatitis</keyword>
</DOC>